"Results from the first year of a two-year National Institutes of Health (NIH) clinical trial show that Avastin, a drug approved to treat some cancers and is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the more expensive FDA-approved drug Lucentis for treating AMD," goes the post from MedicalNewsToday. "The report, from the Comparison of AMD Treatments Trials (CATT), was published online today in the New England Journal of Medicine. Dr. David M. Brown, retinal surgeon at The Methodist Hospital, oversaw the study, part of a multi-centered, single-blind, randomized clinical trial sponsored by the National Eye Institute (NEI), part of the NIH." For more information, go here.
No comments:
Post a Comment